Granite Point Capital Management’s Puma Biotechnology PBYI Stock Holding History

Granite Point Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-1,944	Closed	-$227K	–	98
2015 Q2	$227K	Sell	1,944 -1,056	-35%	-$191K	0.07%	90
2015 Q1	$708K	Sell	3,000 -500	-14%	-$107K	0.26%	62
2014 Q4	$662K	Sell	3,500 -500	-13%	-$111K	0.31%	56
2014 Q3	$954K	Hold	4,000	–	–	0.48%	45
2014 Q2	$264K	Sell	4,000 -2,200	-35%	-$156K	0.18%	80
2014 Q1	$646K	Sell	6,200 -3,800	-38%	-$447K	0.46%	68
2013 Q4	$1.03M	Buy	+10,000	New	+$587K	0.17%	61

Other funds holding PBYI

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Granite Point Capital Management's PBYI Position: Q3 2015 in Review

Granite Point Capital Management sold out of Puma Biotechnology (PBYI) in Q3 2015, closing a stake of 1,944 shares — an estimated $227K sold.

Granite Point Capital Management first reported a position in PBYI in Q4 2013 and held it in 7 quarters. The position peaked at $1.03M in Q4 2013. 163 funds tracked by Wall St. Rank hold PBYI as of Q3 2015.

Granite Point Capital Management reported no remaining Puma Biotechnology position as of Q3 2015 after selling out during the quarter.
Granite Point Capital Management sold 1,944 Puma Biotechnology shares in Q3 2015, an estimated $227K.
Granite Point Capital Management first reported a position in Puma Biotechnology in Q4 2013 and held it in 7 quarters.
Granite Point Capital Management's Puma Biotechnology position peaked at $1.03M in Q4 2013.
163 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2015.

Based on Granite Point Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.